학술논문
Multicenter Randomized Trial of Methylprednisolone vs. Intravenous Immunoglobulins to Treat the Pediatric Inflammatory Multisystem Syndrome—Temporally Associated With SARS-CoV-2 (PIMS-TS): Protocol of the Swissped RECOVERY Trial
Document Type
article
Author
Tatjana Welzel; Nina Schöbi; Maya C. André; Douggl G. N. Bailey; Geraldine Blanchard-Rohner; Michael Buettcher; Serge Grazioli; Henrik Koehler; Marie-Helene Perez; Johannes Trück; Federica Vanoni; Petra Zimmermann; Andrew Atkinson; Carlos Sanchez; Elizabeth Whittaker; Saul N. Faust; Julia A. Bielicki; Luregn J. Schlapbach; the Swissped Recovery Trial
Source
Frontiers in Pediatrics, Vol 10 (2022)
Subject
Language
English
ISSN
2296-2360
Abstract
IntroductionIn 2020, a new disease entitled Pediatric Inflammatory Multisystem Syndrome temporally associated with COVID-19 (PIMS-TS), or Multisystem Inflammatory Syndrome in Children (MIS-C), emerged, with thousands of children affected globally. There is no available evidence based on randomized controlled trials (RCT) to date on the two most commonly used immunomodulatory treatments, intravenous immunoglobulins (IVIG) and corticosteroids. Therefore, the Swissped RECOVERY trial was conducted to assess whether intravenous (IV) methylprednisolone shortens hospital length of stay compared with IVIG.Methods and AnalysisSwissped RECOVERY is an ongoing investigator-initiated, open-label, multicenter two-arm RCT in children and adolescents